List of Excipients in Branded Drug MERILOG

Merilog Excipient Strategy and Commercial Opportunities for Insulin Aspart

Last updated: August 26, 2026

Merilog is an insulin aspart product marketed by Meril Life Sciences. Its commercial potential depends less on novel active-ingredient exclusivity and more on formulation equivalence, injection-device performance, cold-chain reliability, affordability, and access to diabetes channels. The core excipient strategy should prioritize physicochemical stability, preservative performance, compatibility with prefilled pens and pumps, and a cost structure suitable for high-volume human insulin and analog markets.

Public information on Merilog-specific excipient concentrations, patents, Orange Book listings, and litigation is limited. The analysis below uses publicly established insulin aspart formulations and regulatory standards as the technical benchmark.

What is Merilog and which active ingredient does it contain?

Merilog is an insulin aspart product used for rapid-acting mealtime insulin therapy. Insulin aspart is a recombinant insulin analog with a faster absorption profile than regular human insulin when administered subcutaneously. Novo Nordisk originally commercialized insulin aspart under the NovoRapid and NovoLog brands.[1]

Product attribute	Merilog assessment
Brand	Merilog
Manufacturer	Meril Life Sciences
Active ingredient	Insulin aspart
Therapeutic class	Rapid-acting insulin analog
Primary use	Type 1 and type 2 diabetes
Common strength	100 units/mL
Likely dosage forms	Vial, cartridge, or prefilled pen, depending on market
Administration	Subcutaneous injection; pump suitability depends on approved labeling
Commercial comparator	NovoRapid/NovoLog
Key formulation issue	Maintaining monomeric insulin stability during storage, handling, and delivery

The commercial product must control aggregation, deamidation, oxidation, precipitation, adsorption to surfaces, and potency loss. These risks are managed through buffer selection, preservatives, isotonicity agents, zinc coordination, pH control, and container-closure compatibility.

What excipients are used in insulin aspart formulations?

The reference insulin aspart formulation uses a conventional excipient platform. The U.S. NovoLog label identifies glycerin, phenol, metacresol, zinc, disodium phosphate dihydrate, sodium chloride, water for injection, and pH-adjusting agents.[1]

Excipient or component	Primary function	Strategic relevance to Merilog
Glycerol or glycerin	Tonicity adjustment and protein stabilization	Supports injection comfort and solution stability
Phenol	Antimicrobial preservative and structural stabilizer	Helps maintain insulin hexamer structure; concentration must be controlled
Metacresol	Antimicrobial preservative and protein stabilizer	Essential for multidose presentations; may affect tolerability
Zinc ions	Insulin association and structural stabilization	Controls oligomeric state and can affect dissolution behavior
Disodium phosphate	Buffering	Supports pH control during shelf life
Sodium chloride	Tonicity adjustment	Helps match physiological osmolality
Hydrochloric acid and sodium hydroxide	pH adjustment	Required for final formulation control
Water for injection	Vehicle	Must meet parenteral quality standards

A Merilog formulation that follows the established insulin aspart platform would likely use the same functional categories. Exact concentrations must be established through product-specific regulatory records, labeling, or technical documentation.

Why phenol and metacresol matter

Phenol and metacresol are not simple preservatives in insulin products. They also influence insulin self-association. Insulin aspart is supplied in a stabilized form that becomes more rapidly absorbed after dilution and injection into subcutaneous tissue.

Reducing preservative concentration can create several risks:

• Lower multidose antimicrobial protection
• Greater aggregation during repeated vial access
• Changes in insulin hexamer stability
• Altered release and absorption characteristics
• New extractables and leachables or container-closure risks

A reformulated Merilog product would require comparative stability, potency, impurity, preservative-effectiveness, and clinical or bridging justification.

How should Merilog optimize its excipient strategy?

Merilog should use a platform strategy rather than pursue aggressive excipient novelty. The reference formulation is technically mature, widely understood by regulators, and compatible with insulin delivery systems.

1. Preserve the established insulin aspart composition

The lowest-risk approach is a close qualitative and quantitative formulation match to established insulin aspart products. This can reduce development risk in markets that accept biosimilar or follow-on biologic comparability packages.

The priority attributes are:

• Clear, colorless solution
• Controlled pH near the established insulin aspart range
• Low high-molecular-weight protein content
• Stable potency over the labeled shelf life
• Consistent preservative concentration
• Low subvisible particle burden
• Compatibility with pen and vial materials

2. Develop device-specific excipient controls

The same liquid formulation can behave differently in vials, cartridges, disposable pens, and pumps. Contact with elastomeric components, silicone oil, tungsten residues, adhesive components, and cartridge coatings can affect insulin quality.

Merilog should establish separate compatibility packages for:

• Multidose vials
• Reusable pen cartridges
• Disposable prefilled pens
• Insulin pump reservoirs
• Transfer devices and needle systems

The commercial value of device compatibility is significant. A product that is approved for pump use can access intensive insulin therapy and technology-enabled diabetes markets, while a vial-only product is more dependent on price-sensitive channels.

3. Evaluate preservative reduction only if it creates a commercial advantage

A lower-phenol or lower-metacresol formulation could improve injection tolerability for some patients, but it would create additional development and regulatory burdens. The opportunity is more credible in:

• Single-use cartridges
• Short-use hospital presentations
• Pediatric products
• Pump-specific formulations
• Products targeting preservative sensitivity

The development case is weaker for a standard multidose vial because the preservative system is central to microbiological protection and product stability.

4. Use excipient sourcing as a supply-chain differentiator

Merilog can reduce gross-margin volatility by qualifying multiple suppliers for:

• Metacresol
• Phenol
• Pharmaceutical-grade glycerol
• Zinc salts
• Phosphate buffer components
• Elastomeric closures
• Cartridge and pen materials

Excipient dual sourcing requires comparability controls. Changes in grade, trace metals, aldehydes, peroxides, or microbial burden can affect insulin stability even when the excipient has the same compendial name.

What formulations are protected by insulin aspart patents?

The basic insulin aspart composition is unlikely to provide a current broad exclusivity barrier in major markets. Insulin aspart was commercialized more than two decades ago, and foundational composition and use patents have generally reached expiration or are near expiration depending on jurisdiction and patent family.

Potential residual protection can arise from:

• Specific insulin analog formulations
• Stabilized liquid compositions
• Concentrated insulin products
• Pen or cartridge systems
• Pump-compatible presentations
• Manufacturing and purification methods
• Combination products involving glucose-monitoring or delivery systems
• Regional formulation patents with later priority dates

The relevant commercial question is not whether insulin aspart has any patent rights. It is whether a specific Merilog presentation practices an unexpired claim in the target country.

What is the Orange Book status of Merilog?

Merilog is not expected to have a U.S. Orange Book listing unless Meril has obtained FDA approval for a drug product that is eligible for listing. The Orange Book primarily covers approved small-molecule drug products and does not function as the principal patent register for biologic products.

For insulin aspart, regulatory classification depends on the approval pathway and jurisdiction. In the United States, insulin products transitioned from the Federal Food, Drug, and Cosmetic Act framework to the Public Health Service Act on March 23, 2020.[2] FDA-approved insulin products may therefore be subject to biologic reference-product and biosimilar frameworks rather than the conventional small-molecule generic model.

Merilog’s Indian, Gulf, African, or other national regulatory status should be assessed separately. A local approval does not create U.S. interchangeability, Orange Book, or biosimilar rights.

When does Merilog lose exclusivity?

Merilog’s commercial exclusivity is likely determined by regulatory approval rights, trademarks, device protection, manufacturing know-how, and market access rather than by a long remaining composition-patent term.

Exclusivity layer	Merilog relevance
Active-ingredient patents	Foundational insulin aspart rights are generally mature
Formulation patents	May remain relevant for later-filed compositions
Device patents	Can protect pen, cartridge, needle, or delivery mechanisms
Regulatory exclusivity	Depends on country and approval pathway
Trademark	Merilog brand protection can continue if maintained
Manufacturing know-how	May remain valuable even after patent expiry
Distribution contracts	Can delay competitor access without creating statutory exclusivity
Interchangeability status	Can influence substitution and payer uptake

In practice, Merilog is likely to face competitive pressure from Novo Nordisk, Biocon, Wockhardt, Julphar, Sanofi, Eli Lilly, and regional insulin manufacturers. The principal barriers are manufacturing validation, regulatory comparability, cold-chain distribution, device supply, and physician confidence.

What generic entry risks exist for Merilog?

Conventional generic risk

A conventional small-molecule generic pathway is not the most likely competitive model for insulin aspart in all jurisdictions. Competitors may instead use biosimilar, follow-on biologic, abridged biologic, or locally defined comparable-biologic pathways.

Biosimilar and follow-on insulin risk

Insulin aspart is highly exposed to follow-on competition because:

• The molecule is well characterized.
• The reference product has extensive clinical history.
• The formulation platform is established.
• Insulin demand is large and recurring.
• Payers are sensitive to acquisition cost.
• Manufacturing know-how is increasingly available through contract and regional insulin producers.

The key technical barriers are not discovery. They are control of aggregation, impurity profiles, potency, immunogenicity risk, device delivery, and batch-to-batch consistency.

Paragraph IV challenges

A Paragraph IV challenge would be relevant only to patents listed against an applicable U.S. reference product and only where a competitor files an ANDA or another qualifying application. Merilog’s non-U.S. commercial presence does not itself create Paragraph IV exposure.

For insulin aspart, future U.S. challenges are more likely to focus on:

• Device patents
• Cartridge or pen systems
• Concentrated or extended-use presentations
• Manufacturing process claims
• Later-generation formulations

A competitor could also pursue a biosimilar pathway, in which patent certification and litigation mechanics differ from a standard ANDA case.[2]

How strong is the patent estate for Merilog?

Merilog’s likely patent estate is moderate to weak at the molecule level and potentially stronger at the product-system level.

Patent layer	Relative strength	Commercial effect
Insulin aspart molecule	Low	Mature technology and limited remaining life
Basic liquid formulation	Low to moderate	Vulnerable to design-around and prior art
Stabilizer or preservative combinations	Moderate	Can delay direct formulation copying
Pen and cartridge design	Moderate to strong	Can constrain device substitution
Manufacturing process	Moderate	May be difficult to detect and enforce
Packaging and storage system	Low to moderate	Useful for incremental protection
Brand and trade dress	Moderate	Supports substitution resistance, not technical exclusivity

The strongest defensible position would combine a differentiated device, reliable cold-chain performance, locally optimized packaging, and manufacturing process controls that are difficult to replicate without extensive validation.

Which commercial opportunities are available for Merilog?

Affordable rapid-acting insulin

Price-sensitive markets remain the clearest opportunity. Merilog can compete through:

• Lower ex-factory pricing
• Vial presentations for public tenders
• Reusable pens with lower lifetime cost
• Regional fill-finish operations
• Government diabetes programs
• Hospital and clinic supply contracts

A vial-first strategy may maximize volume but can reduce patient convenience and adherence. A pen-first strategy can improve usability and brand value while increasing device cost.

Biosimilar insulin channels

Merilog can expand through countries that have established pathways for comparable biologics or follow-on insulins. Regulatory credibility depends on analytical similarity, clinical pharmacology, immunogenicity, and device comparability.

Pump-compatible insulin

Pump compatibility can create a higher-value niche. The formulation must withstand prolonged reservoir exposure, mechanical agitation, temperature excursions, and extended in-device residence. Pump claims and labeling require product-specific evidence.

Pediatric and adherence-focused products

Commercial differentiation may come from:

• Lower injection discomfort
• Smaller-volume delivery
• Pen dose increments suitable for children
• Clear dose windows
• Simplified storage instructions
• Patient-support programs
• Combination access with glucose monitoring

These opportunities are primarily formulation-device and service opportunities rather than new-molecule opportunities.

Emerging markets

The highest-volume potential is likely in India, Southeast Asia, the Middle East, Africa, and selected Latin American markets. Local production, government procurement eligibility, reliable refrigeration, and distributor reach will have greater commercial impact than additional excipient innovation.

How does Merilog compare with NovoRapid and other insulin aspart products?

Factor	Merilog	NovoRapid/NovoLog	Commercial implication
Molecule	Insulin aspart	Insulin aspart	Limited molecule-level differentiation
Formulation maturity	Expected to use established platform	Extensive stability and clinical history	Reference product has confidence advantage
Device ecosystem	Depends on Meril’s pen and cartridge network	Broad proprietary device ecosystem	Device integration can favor Novo Nordisk
Price position	Potentially lower	Premium or reference pricing	Merilog can compete in tenders and cash-pay markets
Physician familiarity	Developing	High	Medical education and real-world data matter
Patent exposure	Product-specific and jurisdictional	Device and later-generation patent exposure	Freedom-to-operate analysis remains necessary
Biosimilar vulnerability	High as a follow-on product	High from competing follow-on products	Price competition is likely
Supply-chain opportunity	Regional manufacturing	Established global network	Local production can reduce landed cost

What litigation and settlement risks affect Merilog?

No Merilog-specific patent litigation or settlement agreement is established in the information reviewed. The principal litigation risks are likely to involve:

• Alleged infringement of pen or cartridge patents
• Biosimilar approval challenges
• Manufacturing-process patents
• Trade-secret disputes involving insulin production
• Trademark conflicts involving Merilog or similar names
• Regulatory challenges to interchangeability or substitution
• Product-liability claims involving dosing or device malfunction

Settlement agreements could restrict launch timing, manufacturing sites, territories, or device configurations. A freedom-to-operate review should cover both the insulin formulation and the delivery system because a noninfringing insulin formulation can still be blocked by a proprietary pen or cartridge.

What regulatory strategy should support Merilog’s growth?

Meril should maintain separate regulatory strategies for the drug substance, finished product, and delivery device.

Key regulatory workstreams include:

1. Analytical comparability against a recognized insulin aspart reference product.
2. Stability studies under long-term, accelerated, in-use, and temperature-excursion conditions.
3. Preservative-effectiveness testing for multidose presentations.
4. Extractables and leachables testing for pens and cartridges.
5. Container-closure integrity testing.
6. Immunogenicity assessment.
7. Device dose-accuracy and human-factors validation.
8. Pump compatibility studies where pump labeling is sought.
9. Cold-chain qualification and distribution monitoring.
10. Country-specific substitution and interchangeability requirements.

FDA guidance for insulin products emphasizes comparative analytical and clinical evaluation, including pharmacokinetic and pharmacodynamic studies where applicable.[2] ICH Q5C and related biologic-quality principles are relevant to stability and characterization strategy.[3]

Key Takeaways

• Merilog is an insulin aspart product whose main commercial opportunity is affordable rapid-acting insulin.
• The lowest-risk excipient platform is the established insulin aspart system based on glycerol, phenol, metacresol, zinc, phosphate buffer, sodium chloride, water, and pH adjusters.
• Excipient novelty is less valuable than formulation equivalence, device compatibility, cold-chain reliability, and manufacturing scale.
• Foundational insulin aspart patents are mature, but device, formulation, manufacturing, and packaging patents can still create market-entry barriers.
• U.S. Orange Book and Paragraph IV analysis depends on the specific FDA-approved product and pathway; Merilog’s non-U.S. status does not establish U.S. rights.
• The strongest commercial segments are public tenders, emerging markets, reusable pens, pump-compatible products, and biosimilar or follow-on insulin channels.
• Merilog’s patent strength is likely limited at the molecule level but can be improved through device, formulation, manufacturing, and packaging protection.
• The principal competitive threat is price-based follow-on insulin entry supported by regional manufacturing and government procurement.

FAQs

Can Merilog use a preservative-free insulin aspart formulation?

A preservative-free formulation may be feasible for single-use presentations, but it is less suitable for multidose vials or cartridges because antimicrobial protection would be reduced. The product would require new stability, microbiological, container-closure, and regulatory data.

Is Merilog interchangeable with NovoRapid?

Interchangeability depends on the approval status and legal standards in each country. Similar active ingredients and excipients do not automatically establish regulatory interchangeability or automatic pharmacy substitution.

Can Merilog be used in an insulin pump?

Pump use depends on Merilog-specific labeling and compatibility data. A formulation suitable for subcutaneous injection is not automatically approved for pump reservoirs or extended in-device use.

Which excipient is most important for Merilog stability?

No single excipient controls all stability risks. The preservative system, zinc concentration, pH, buffer, and container-closure system operate together to maintain insulin structure and potency.

What is the main commercial threat to Merilog?

The main threat is lower-priced follow-on insulin aspart from regional manufacturers, particularly products distributed through public tenders and national diabetes programs.

References

1. Novo Nordisk. (2023). NovoLog insulin aspart injection prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2020). Clinical immunogenicity considerations for recombinant insulin products: Guidance for industry. U.S. Department of Health and Human Services.

3. International Council for Harmonisation. (2003). Q5C: Quality of biotechnological products: Stability testing of biotechnological/biological products. ICH.

4. European Medicines Agency. (2023). NovoRapid: EPAR product information. European Medicines Agency.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.